Assessing the relationship between FibroScan and laboratory parameters in evaluating hepatic fibrosis in patients with non-alcoholic fatty liver disease
DOI:
https://doi.org/10.18203/2320-6012.ijrms20243358Keywords:
APRI, FIB-4 score, Hepatic fibrosis, NAFLD, AST/ALT ratioAbstract
Background: The gold standard for diagnosing steatosis, grading fibrosis, and determining its severity is liver biopsy (LB). An alternate, less expensive, and trouble-free technique for accurately identifying and measuring steatosis is the controlled attenuation parameter (CAP) value acquired with FibroScan.3 Hence, the present study was undertaken to correlate laboratory parameters (AST/ALT ratio, AST platelet ratio index, Fib-4 score) with FibroScan as a marker of hepatic fibrosis in non-alcoholic fatty liver disease (NAFLD) patients.
Methods: 68 patients diagnosed to have NAFLD as per imaging were subjected to FibroScan using transient elastography within 2 weeks. Blood sample was taken for various lab tests. Area under receiver operating curve was plotted for predicting advanced fibrosis. Sensitivity and specificity were calculated.
Results: Based on ROC curves of APRI, FIB-4, and AST/ALT ratio for the detection of F2 of liver fibrosis the best index to diagnose F2 from lower stages of liver fibrosis was APRI, with an AUROC curve of 0.747 (95% confidence interval [CI] 0.599–0.894). The optimal cut-off of APRI was 0.276 for this purpose, with a sensitivity of 70.83%, specificity of 79.55%, PPV of 65.38%, NPV of 83.3%, and DA of 76.47%.
Conclusions: To conclude, it was found that the fibrosis stages increased significantly with APRI scores and Fib-4 score. AST/ALT ratio decreased with increase in FibroScan grade, however, mean of AST/ALT ratio was more in F2 grade than F1 with statistically non- significant relation. This can eliminate the need for LB in patients without clear indication.
References
Pouwels S, Sakran N, Graham Y, Leal A, Pintar T, Yang W, et al. Non-alcoholic fatty liver disease (NAFLD): a review of pathophysiology, clinical management and effects of weight loss. BMC Endocr Disord. 2022;22(1):63.
Shrestha R, Sudhamshu KC, Thapa P, Pokharel A, Karki N, Jaishi B. Estimation of liver fat by FibroScan in patients with nonalcoholic fatty liver disease. Cureus. 2021;13(7):15.
Danaf L, Hussein KM, Fayad E, Hussain A, Farhat S. Correlation between FibroScan and laboratory tests in non-alcoholic fatty liver disease/non-alcoholic steatohepatitis patients for assessing liver fibrosis. World J Hepatol. 2022;14(4):744-53.
Sumida Y, Nakajima A, Itoh Y. Limitations of liver biopsy and non-invasive diagnostic tests for the diagnosis of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. World J Gastroenterol. 2014;20(2):475-85.
Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Circulation. 2005;112(17):2735-52.
Gaia S, Carenzi S, Barilli AL, Bugianesi E, Smedile A, Brunello F, et al. Reliability of transient elastography for the detection of fibrosis in non-alcoholic fatty liver disease and chronic viral hepatitis. J Hepatol. 201;54(1):64-71.
Fallatah HI, Akbar HO, Fallatah AM. FibroScan Compared to FIB-4, APRI, and AST/ALT Ratio for Assessment of Liver Fibrosis in Saudi Patients with Nonalcoholic Fatty Liver Disease. Hepat Mon. 2016;16(7):e38346.
Vernon G, Baranova A, Younossi ZM. Systematic review: The epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther. 2011;34:274-85.
Sanyal D, Mukherjee P, Raychaudhuri M, Ghosh S, Mukherjee S, Chowdhury S. Profile of liver enzymes in non-alcoholic fatty liver disease in patients with impaired glucose tolerance and newly detected untreated type 2 diabetes. Indian J Endocrinol Metab. 2015;19(5):597-601.
Tous M, Ferré N, Camps J, Riu F, Joven J. Feeding apolipoprotein E-knockout mice with cholesterol and fat enriched diets may be a model of non-alcoholic steatohepatitis. Molecular and cellular biochemistry. 2005;268:53-8.
Lee L, Alloosh M, Saxena R, Van Alstine W, Watkins BA, Klaunig JE, et al. Nutritional model of steatohepatitis and metabolic syndrome in the Ossabaw miniature swine. Hepatology. 2009;50(1):56-67.
Kuipers F, Van Ree JM, Hofker MH, Wolters H, Veld GT, Havinga R, Vonk RJ, Princen HM, Havekes LM. Altered lipid metabolism in apolipoprotein E-deficient mice does not affect cholesterol balance across the liver. Hepatology. 1996;24(1):241-7.
Cheng HY, Wang HY, Chang WH, Lin SC, Chu CH, Wang TE, et al. Nonalcoholic fatty liver disease: prevalence, influence on age and sex, and relationship with metabolic syndrome and insulin resistance. Int J Gerontol. 2013;7(4):194-8.
Kim EJ, Kim BH, Seo HS, Lee YJ, Kim HH, Son HH, et al. Cholesterol-induced non-alcoholic fatty liver disease and atherosclerosis aggravated by systemic inflammation. PLoS One. 2014;9(6):e97841.
Arguello G, Balboa E, Arrese M, Zanlungo S. Recent insights on the role of cholesterol in non-alcoholic fatty liver disease. Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease. 2015;1852(9):1765-78.
Williams AL, Hoofnagle JH. Ratio of serum aspartate to alanine aminotransferase in chronic hepatitis. Relationship to cirrhosis. Gastroenterology. 1988;95(3):734-9.
Hall P, Cash J. What is the real function of the liver 'function' tests? Ulster Med J. 2012;81(1):30-6.
Moosavy SH, Eftekhar E, Davoodian P, Nejatizadeh A, Shadman M, Zare S, et al. AST/ALT ratio, APRI, and FIB-4 compared to FibroScan for the assessment of liver fibrosis in patients with chronic hepatitis B in Bandar Abbas, Hormozgan, Iran. BMC Gastroenterol. 2023;23(1):145.
Amernia B, Moosavy SH, Banookh F, Zoghi G. FIB-4, APRI, and AST/ALT ratio compared to FibroScan for the assessment of hepatic fibrosis in patients with non-alcoholic fatty liver disease in Bandar Abbas, Iran. BMC Gastroenterol. 2021;21(1):453.
Sha FR, Pk MU, Abuelezz NZ, Pervin R, Talukder RI, Begum M, et al. Investigating the efficiency of APRI, FIB-4, AAR and AARPRI as noninvasive markers for predicting hepatic fibrosis in chronic hepatitis B patients in Bangladesh. Open Microbiol J. 2019;13(1):e50.
Yue W, Li Y, Geng J, Wang P, Zhang L. Aspartate aminotransferase to platelet ratio can reduce the need for transient elastography in Chinese patients with chronic hepatitis B. Medicine. 2019;98(49):10.
World Health O. Guidelines for the prevention care and treatment of persons with chronic hepatitis B infection: Mar-15: World Health Organization. 2015. Available at: https://www.afro.who.int/sites/default/files/2017-06/9789241549059_eng.pdf. Accessed on 17th March 2024.
Shi KQ, Tang JZ, Zhu XL, Ying L, Li DW, Gao J, et al. Controlled attenuation parameter for the detection of steatosis severity in chronic liver disease: a meta‐analysis of diagnostic accuracy. J Gastroenterol Hepatol. 2014;29(6):1149-58.
Friedrich-Rust M, Ong MF, Martens S, Sarrazin C, Bojunga J, Zeuzem S, et al. Performance of transient elastography for the staging of liver fibrosis: a meta-analysis. Gastroenterology. 2008;134(4):960-74.
Yoneda M, Mawatari H, Fujita K, Endo H, Iida H, Nozaki Y, et al. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with nonalcoholic fatty liver disease (NAFLD). Digestive Liver Disease. 2008;40(5):371-8.